Introduction
============

Aggressive vertebral haemangiomas (AVH) are benign vascular tumours, which breach the posterior cortical wall of the affected vertebra, may affect anterior column stability, and compress the spinal cord epidurally \[[@B1]\]. Due to the benign nature of the tumour, metastatic spreading does not occur, but impaired vertebral stability or myelopathy may require surgical treatment for stabilisation and decompression \[[@B2]\]. A representative case is presented in [Fig. 1](#F1){ref-type="fig"}.

Depending on the affected vertebral level and the anterior and posterior extent of the lesion, there are combined surgical accesses to decompress and stabilise AVH. Due to high vascularisation of haemangiomas, copious bleeding may complicate surgery, and can even be life-threatening \[[@B1]\].

Embolisation of spinal tumours *via* flouroscopically-controlled endovascular intervention aims at choking off the blood flow in the tumour by blocking the feeding arteries, and thus reducing surgical blood loss. Many substances can be used for embolisation depending of the size of the vessel and the desired length of occlusion \[[@B3]\]. Liquid embolic agents (i.e., Onyx) \[[@B4]\], sclerosing agents (i.e., ethanol) \[[@B5]\], particulate embolic agents (i.e., polyvinyl ethanol) \[[@B6]\], and mechanical occlusion devices (i.e., coils) are commonly used as embolising agents.

Yet, many spinal interventionalists fear the possibility of ischaemic spinal cord injury as a complication of the embolisation procedure due to accidental occlusion of unrecognised radiculomedullary arteries. Surgeons might therefore avoid performing embolisation and rather treat bleeding surgically. Possible complications of spinal tumour embolisation are (1) emboli washout with vascular occlusion (i.e., spinal cord ischaemia, stroke, myocardial infarction, peripheral arterial occlusion) \[[@B7]\], (2) bleeding due to early revascularisation caused by rapid enzymatic degradation of the embolisation agents (i.e., gelfoam) \[[@B8]\], and (3) allergic reactions to the embolising agents \[[@B9]\].

Kobayashi et al. \[[@B7]\] reviewed 62 patients who underwent preoperative embolisation of spinal tumours. In their cohort, the degree of embolisation itself did not have any significant effect on perioperative blood loss, but surgical invasiveness did (*p*\<0.001). Therefore, the impact of preoperative embolisation should be questioned and its benefits should be weighed against possible harms. Until now, a meta-analysis of the effect of embolisation on surgical bleeding in the published case reports and case series on AVH has not been performed. This review will summarise the weak evidence for treatment of AVH, present a meta-analysis of bleeding related to the use of embolisation prior to surgery, and assess whether preoperative embolisation reduces blood loss during resection and/or decompression of symptomatic aggressive vertebral haemangioma.

Materials and Methods
=====================

This systematic review was registered in the PROSPERO database (CRD42014008862). On March 7th, 2014, a literature search was performed with PubMed Medline, Web of Science, and Ovid Medline using the search terms \"(aggressive OR spinal cord) AND (spinal OR vertebral) AND haemangioma\".

Limits were set to publications since 1990. The PubMed Medline search was limited to \"\[Title/Abstract\]\", and the Ovid Medline search was limited to \"title\".

Titles and abstracts were obtained from the respective search engines. All full-texts could be obtained from the university libraries or from openly accessible publications.

Only studies on extradural thoracic and lumbar aggressive haemangiomas were included since embolisation of cervical haemangioma is relatively contraindicated.

Case reports of AVH becoming symptomatic during pregnancy were excluded since embolisation is contraindicated in these patients due to the possible harm to the unborn. The case presented in this study was also included. The amount of bleeding (mL) was defined as the primary outcome.

The data was treated as a between-group design with two independent groups; one treatment group (embolisation) and one control group (no embolisation). The reported means, standard deviation, and number of participants in the included studies were used to compute the means, standard deviations, and number of participants in the treatment and control groups, respectively. Sample sizes were taken into account when calculating the two groups\' means by calculating the weighted means. The standard deviations of the treatment and control groups were calculated by first computing the sum of squares. In a subsequent step, the sum of squares was used to calculate the variances and the standard deviations. The means, standard deviations, and number of participants in the two groups were submitted to an independent samples *t*-test. The effect size was calculated as Cohen\'s d. If not indicated otherwise, values are presented as mean±standard deviation.

Subgroup analysis was not performed and heterogeneity was not assessed. Due to the low quality of evidence and the fact that only case reports were available, sensitivity analysis was not performed.

Two authors assessed the risk of bias of included studies separately according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group guidelines for assessing risk of bias \[[@B10]\]. All included studies were case reports and case series; thus, both selection bias and reporting bias can be assumed. The strength of evidence was estimated and recommendations were given using the GRADE guidelines \[[@B11]\].

Results
=======

The electronic search retrieved 399 publications that were screened by two co-authors. Among these, 54 publications were potentially eligible for inclusion. After full-text review, 18 publications were included ([Fig. 2](#F2){ref-type="fig"}). While checking for outliers, the case report by Alexander et al. \[[@B2]\] was excluded because the value in a single participant was more than 6 standard deviations away from the mean of the control group. All 17 included studies were case reports or case series. No comparative study was included. Twelve out of the 17 included studies were single case reports.

Among the 51 included patients, 32 were females. The mean patient age was 44±19 years (range, 9-77 years). Also, 83% of AVH involved the thoracic spine.

Various types of interventions were used in the included studies. They varied from posterior decompression and vertebroplasty to circumferential *en-bloc* spondylectomy and stabilisation. Despite the fact that the different procedures are not equivalent with regard to invasiveness of the approach, selection was not performed in this context.

The postoperative neurological outcomes were generally positive in the published cases, irrespective of the surgical method. Only one out of the 51 cases did not show postoperative improvement ([Table 1](#T1){ref-type="table"}) \[[@B12][@B13][@B14][@B15][@B16][@B17][@B18][@B19][@B20][@B21][@B22][@B23][@B24][@B25]\].

The analysis indicated that there was a significant difference in the amount of blood loss between the treatment group and the control group (*t* \[49\]=2.59; *p*=0.013; 95% CI, 143-1,048; *d*=0.73). Patients in the embolised treatment group (980±683 mL) bled less than patients in the non-embolised control group (1,629±946 mL). The analysis suggests that embolisation causes reduction in bleeding during surgery.

Discussion
==========

The available literature supports the use of preoperative embolisation in cases of AVH. The variability in effectiveness of embolisation is well reflected in these results. Embolisation does not seem to be the only factor contributing to reduction in bleeding; other factors such as surgical technique, proper anaesthesia (i.e., using low positive end-expiratory pressure), and clotting capacity of the patients also play an important role, thus diminishing the overall effect of embolisation.

With regard to spinal surgery, the amount of surgical bleeding could be related to morbidity and mortality in the postoperative course \[[@B26]\]. Not only transfusion risks but also cardiovascular and pulmonary complications increase with greater blood loss \[[@B27]\].

Preoperative embolisation is a relatively safe procedure and reported complications are rare. Other than the transient post-embolisation syndrome with low-grade fever, pain, nausea, vomiting, and an elevated white blood cell count, serious adverse events due to accidental vascular occlusion are limited to anecdotal case reports \[[@B3]\].

The quality of evidence is very low. Seventeen studies were included, and all studies were either case reports or case series ([Table 2](#T2){ref-type="table"}). With an increase in the size of AVH, the surgeon may be more inclined to use preoperative embolisation. Blinding was not performed in the included case reports. Not all studies reported the amount of bleeding, and 36 studies were excluded due to incomplete data.

A significant publication bias must be assumed since case reports are published only if they present a rare and unique entity. Cases with incomplete radiographic examinations, suboptimal outcome, or missing documentation are often not publishable.

Only selected databases were searched using a rather conservative search string. Studies published before 1990 were not included in the study. Therefore, there is a possibility that not all studies were identified.

Conclusions
===========

This meta-analysis found-with reservations due to the above-mentioned limitations-a significant reduction in surgical bleeding and a large treatment effect of preoperative embolisation ([Table 3](#T3){ref-type="table"}).

The authors agreed with the strong recommendation of embolisation prior to resection surgery for symptomatic AVH \[[@B28]\].

It has been shown that not only embolisation, but surgical invasiveness also plays an important role in surgical bleeding in tumour surgery \[[@B7]\]. Due to the benign characteristics of AVH, the least invasive procedure must be applied to treat this tumour with minimal blood loss and complications. However, biomechanical considerations may compel us to perform resection and reconstruction of anterior column elements, which are associated with greater blood loss \[[@B29]\].

Besides this, similar to spinal tumour surgery, selective endovascular embolisation also undeniably requires skills with a learning curve \[[@B30]\]. The cases with greater blood loss despite embolisation indicate that it was very likely that all feeding arteries were not occluded. To improve the success rate of embolisation, a specific training program may be helpful.

There are severe methodological limitations in the meta-analysis of the published cases since significant selection and publication biases must be assumed. The inconsistency in the results reflected by the confidence interval leaves a huge question mark over the conclusion of this study.

Further research could improve the available evidence. Pooling of prospectively collected national registry data could increase the number of included cases. Randomised controlled trials comparing embolisation to control are not feasible due to the small number of cases.
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![Representative case of a 64-year-old man with progressive myelopathy below T6 (ASIA C). **(A-C)** Computed tomography (CT) scans revealed vertical striations on the T6 vertebral body, highly suggestive of haemangioma. **(D)** T1 magnetic resonance imaging with gadolinium contrast highlighted the epidural portion of the tumour. **(E)** After placement of the first coil, the haemangioma was still highly vascularised. **(F)** The second coil successfully occluded the feeding arteries. **(G)** The tumour was stabilised by posterior instrumentation of T4-T8, the posterior portion of the haemangioma was resected, and the vertebral body was replaced by an expandable titanium cage and autologous bone-graft. The amount of bleeding was 2,060 mL, and 550 mL red blood cell concentrate was autotransfused from the cell saver. No allogeneic blood transfusion was required. **(H, I)** Postoperative CT scans showed proper decompression and adequate stabilisation. The patient recovered completely from myelopathy within two months (ASIA E). ASIA, American Spinal Injury Association classification.](asj-9-483-g001){#F1}

![Study flow diagram.](asj-9-483-g002){#F2}

###### Characteristics of studies

![](asj-9-483-i001)

f/u, follow-up; CR, case report; CS, case series; JOA, Japanese Orthopaedic Association score; ASIA, American Spinal Injury Association classification.

###### Bleeding with vs. without embolisation
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###### Summary of findings
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GRADE Working Group grades of evidence.

\- High quality: further research is very unlikely to change our confidence in the estimate of effect.

\- Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

\- Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

\- Very low quality: we are very uncertain about the estimate.

AVH, aggressive vertebral haemangiomas.
